Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKLB1028 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Latest Information Update: 03 Oct 2021
At a glance
- Drugs SKLB 1028 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 11 Aug 2016 New trial record